Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology
Based on a scientifically solid proof of concept in dogs and cats, a licensed international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding and to become profitable within 36 months of raising funds.
BOSTON, July 15, 2022 /PRNewswire/ -- CureLab Veterinary, a newly formed animal-health sister company to the human-focused Curelab Oncology, has launched with exclusive worldwide rights to apply CureLab Oncology patents for treating dogs, cats, and horses. The first target market for CureLab Veterinary’s licensed DNA therapeutic will be to treat breast cancer in dogs and cats.
Cancer is the primary cause of death for dogs in the United States, and in Europe, canine cancer incidence is even higher because fewer dogs are neutered. In published translational studies, the licensed p-62 DNA plasmid technology successfully treated breast cancer in 10 out of 11 dogs. CureLab Veterinary plans to publish both safety and effectiveness data against breast cancers in both dogs and cats. Additionally, the licensed technology may be used as well to treat other canine cancers such as melanoma plus to mitigate diseases of chronic inflammation.
“Cancer and osteoarthritis have a common contributing factor, chronic inflammation. Thus, our second target, after responsive cancers, will be osteoarthritis, which affects 70 percent of older dogs and 100 percent of older cats,” said Robert Devlin, DVM, president of CureLab Veterinary.
The CureLab Veterinary team has more than 25 years of successful US and international clinical and business experience in R&D and marketing of veterinary therapeutic products. The initial focus of the team is the approval process for CureLab Veterinary’s licensed therapeutic through the United States Department of Agriculture Center for Veterinary Biologics (USDA-CVB).
“Receiving market authorization through the USDA-CVB approval process is cost-efficient and relatively fast. FDA and USDA officials have reviewed CureLab Veterinary’s file and have stated we should proceed through the USDA-CVB approval process. The first meeting with USDA officials was very encouraging,” said Devlin.
To streamline the regulatory process, the company has engaged consultants with many years of experience with the USDA. CureLab Veterinary has also formed a comprehensive scientific advisory board of key opinion leaders in veterinary medicine with successful academic and private industry track records. These advisors include oncologists, gastroenterologists, orthopedists, dermatologists, and other veterinary professionals.
Currently, the company is interviewing and evaluating contract manufacturers to produce its product and assist CureLab through the approval process and market introduction.
CureLab Veterinary intends to raise initial financing through a crowdfunding campaign. The company expects to be profitable within three years of funding.
About Elenagen and ElenaVet
CureLab Oncology’s lead product, Elenagen, is a DNA-encoding gene called p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (such as chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor. For the veterinary market, CureLab Veterinary will market the licensed therapy as ElenaVet®, which will be modified for the veterinary marketplace. To learn more, visit curelabveterinary.com .
About CureLab Oncology
CureLab Oncology Inc. is a clinical-stage immuno-oncology biotech company headquartered in the greater Boston area. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications in humans. To learn more, visit curelab.com.
Media contact:
Tim Cox, ZingPR, [email protected]
SOURCE CureLab Oncology Inc.
Share this article